Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 7/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 7/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 7/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 7/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 7/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1135824 | 0.83 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1135906 | 0.75 | GRIN2D (0.53) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30248943 | 0.74 | ELANE (0.49) | ELANEKDM4EALDH1A1GLAADRB2 | |
| SCHEMBL19335541 | 0.74 | EPHX2 (0.62) | ELANE | |
| SCHEMBL18457608 | 0.74 | ELANE (0.45) | ELANECHEK1MAPTLMNA | |
| SCHEMBL29607284 | 0.72 | ELANE (0.74) | ELANEMAPTALDH1A1ADRB2LMNA | |
| SCHEMBL1135619 | 0.72 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14906565 | 0.70 | ADRB2 (0.47) | KDM4EALDH1A1ADRB2ADRB1MEN1 | |
| SCHEMBL1135811 | 0.69 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL27831640 | 0.69 | ELANE (0.46) | ELANECYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285786-B1 | QUINOXALINEDIONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-10-09 | — | — | EP | claimed |
| US-8329698-B2 | Quinoxalinedione derivatives which are activators of AMPK-activated protein kinase | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-12-11 | — | — | US | claimed |
| JP-2011524384-A | — | — | 2011-09-01 | — | — | JP | claimed |
| US-20110130404-A1 | QUINOXALINEDIONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-06-02 | — | — | US | claimed |
| EP-2285786-A1 | QUINOXALINEDIONE DERIVATIVES | Merck Patent GmbH (DE) | 2011-02-23 | — | — | EP | claimed |
| WO-2009152909-A1 | QUINOXALINEDIONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-23 | — | — | WO | claimed |
| US-8674097-B2 | Quinoxalinedione derivatives useful as activators of AMPK-activated protein kinase | MERCK PATENT GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| EP-2285786-B1 | QUINOXALINEDIONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-20120322806-A1 | QUINOXALINEDIONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-20 | — | — | US | disclosed |
| US-8329698-B2 | Quinoxalinedione derivatives which are activators of AMPK-activated protein kinase | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20110130404-A1 | QUINOXALINEDIONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| EP-2285786-A1 | QUINOXALINEDIONE DERIVATIVES | Merck Patent GmbH (DE) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009152909-A1 | QUINOXALINEDIONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130404-A1 | QUINOXALINEDIONE DERIVATIVES | GLP1R, GPR119, NDUFS3 | ELANE 2633/4885GRIN2D 2417/4885GRIN3B 3796/4885 |
| US-20120322806-A1 | QUINOXALINEDIONE DERIVATIVES | GLP1R, GPR119, NDUFS3 | ELANE 2633/4885GRIN2D 2417/4885GRIN3B 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.